Cris Constantinescu

List of Publications by Year
in descending order

220	10,066	36203	43802
papers	citations	51 h-index	91 g-index

228	228	228	13042
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The impact of smoking cessation on multiple sclerosis disease progression. Brain, 2022, 145, 1368-1378.	3.7	16
2	Smoking Attributable Risk in Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 840158.	2.2	11
3	Easy to interpret coordinate based meta-analysis of neuroimaging studies: Analysis of brain coordinates (ABC). Journal of Neuroscience Methods, 2022, 372, 109556.	1.3	4
4	The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. Journal of the Neurological Sciences, 2022, 436, 120188.	0.3	3
5	Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol. International Journal of Pharmaceutics, 2022, 624, 121947.	2.6	7
6	Effects of substance P on human cerebral microvascular endothelial cell line hCMEC/D3 are mediated exclusively through a truncated NK-1 receptor and depend on cell confluence. Neuropeptides, 2022, 95, 102265.	0.9	1
7	Dorsolateral prefrontal circuit effective connectivity mediates the relationship between white matter structure and PASAT â€3 performance in multiple sclerosis. Human Brain Mapping, 2021, 42, 495-509.	1.9	10
8	PAF-R on activated T cells: Role in the IL-23/Th17 pathway and relevance to multiple sclerosis. Immunobiology, 2021, 226, 152023.	0.8	8
9	Investigating Brain Microstructural Alterations in Type 1 and Type 2 Diabetes Using Diffusion Tensor Imaging: A Systematic Review. Brain Sciences, 2021, 11, 140.	1.1	18
10	Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 691-697.	0.2	9
11	Neurological Disorders Associated With COVID-19 Hospital Admissions: Experience of a Single Tertiary Healthcare Center. Frontiers in Neurology, 2021, 12, 640017.	1.1	6
12	Experimental infection with the hookworm, Necator americanus, is associated with stable gut microbial diversity in human volunteers with relapsing multiple sclerosis. BMC Biology, 2021, 19, 74.	1.7	17
13	Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 162, 43-49.	2.0	19
14	Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. Journal of the Neurological Sciences, 2021, 426, 117437.	0.3	19
15	Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle. Pharmaceutics, 2021, 13, 1349.	2.0	9
16	Investigating Microstructural Changes in White Matter in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Neurite Orientation Dispersion and Density Imaging. Brain Sciences, 2021, 11, 1151.	1.1	14
17	Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. Journal of the Neurological Sciences, 2021, 431, 120039.	0.3	5
18	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110576.	1.5	5

#	Article	IF	Citations
19	Pet Ownership and Multiple Sclerosis during COVID-19. International Journal of Environmental Research and Public Health, 2021, 18, 12683.	1.2	4
20	Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success. Multiple Sclerosis Journal, 2020, 26, 266-271.	1.4	11
21	Coordinate based meta-analysis of networks in neuroimaging studies. NeuroImage, 2020, 205, 116259.	2.1	6
22	MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. Journal of Neurology, 2020, 267, 359-368.	1.8	22
23	Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality. European Journal of Neurology, 2020, 27, 105-112.	1.7	26
24	A different response to cytomegalovirus (CMV) and Epsteinâ€“Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controls. Journal of Infection, 2020, 80, 320-325.	1.7	16
25	Cognitive rehabilitation for attention and memory in people with multiple sclerosis: a randomized controlled trial (CRAMMS). Clinical Rehabilitation, 2020, 34, 229-241.	1.0	10
26	Iron Rims as an Imaging Biomarker in MS: A Systematic Mapping Review. Diagnostics, 2020, 10, 968.	1.3	11
27	Increased IL-2 and Reduced TGF-Î² Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis. Biomedicines, 2020, 8, 226.	1.4	6
28	Maintenance Intravenous Immunoglobulin Treatment for Multiple Sclerosis Coexisting with Ehlers-Danlos Syndrome and Muir-Torre Syndrome: A Case Study. Neurology and Therapy, 2020, 9, 605-610.	1.4	1
29	An Absence of Epsteinâ€“Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination. Vaccines, 2020, 8, 487.	2.1	2
30	Localised Grey Matter Atrophy in Multiple Sclerosis and Clinically Isolated Syndromeâ€”A Coordinate-Based Meta-Analysis, Meta-Analysis of Networks, and Meta-Regression of Voxel-Based Morphometry Studies. Brain Sciences, 2020, 10, 798.	1.1	7
31	Congenital monocular elevation deficiency associated with a novelTUBB3gene variant. British Journal of Ophthalmology, 2020, 104, 547-550.	2.1	8
32	Hookworm Treatment for Relapsing Multiple Sclerosis. JAMA Neurology, 2020, 77, 1089.	4.5	39
33	Delirium as a presenting feature in COVID-19: Neuroinvasive infection or autoimmune encephalopathy?. Brain, Behavior, and Immunity, 2020, 88, 68-70.	2.0	54
34	Graph Theoretic Analysis of Brain Connectomics in Multiple Sclerosis: Reliability and Relationship with Cognition. Brain Connectivity, 2020, 10, 95-104.	0.8	23
35	Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT. Health Technology Assessment, 2020, 24, 1-182.	1.3	14
36	Reduced Myelin Signal in Normal-appearing White Matter in Neuromyelitis Optica Measured by 7T Magnetic Resonance Imaging. Scientific Reports, 2019, 9, 14378.	1.6	13

#	Article	IF	Citations
37	Epilepsy and associated mortality in patients with multiple sclerosis. European Journal of Neurology, 2019, 26, 342.	1.7	16
38	Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opinion on Pharmacotherapy, 2019, 20, 143-150.	0.9	33
39	Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis. Neurology and Therapy, 2019, 8, 45-57.	1.4	20
40	Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis. Journal of Neuroimmunology, 2019, 329, 24-34.	1.1	41
41	Coordinate based meta-analysis does not show grey matter atrophy in narcolepsy. Neuroscience and Biobehavioral Reviews, 2019, 102, 427-429.	2.9	6
42	Recent developments in interferon-based therapies for multiple sclerosis. Expert Opinion on Biological Therapy, 2018, 18, 665-680.	1.4	21
43	Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited. European Journal of Neurology, 2018, 25, 905-906.	1.7	2
44	Gastrointestinal influences in multiple sclerosis: Focus on the role of the microbiome. Clinical and Experimental Neuroimmunology, 2018, 9, 2-12.	0.5	4
45	Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. Nicotine and Tobacco Research, 2018, 20, 589-595.	1.4	32
46	Sevenâ€Tesla Magnetization Transfer Imaging to Detect Multiple Sclerosis White Matter Lesions. Journal of Neuroimaging, 2018, 28, 183-190.	1.0	10
47	Hypothermia in Multiple Sclerosis: Beyond the Hypothalamus? A Case Report and Review of the Literature. Case Reports in Neurological Medicine, 2018, 2018, 1-16.	0.3	2
48	Neuro-BehÃ§etâ€™s Disease â€“ Clinical Features, Diagnosis and Differential Diagnosis. European Neurological Review, 2018, 13, 93.	0.5	3
49	Coordinate based random effect size meta-analysis of neuroimaging studies. NeuroImage, 2017, 153, 293-306.	2.1	23
50	Decreased interferon-Î² induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 233-238.	1.0	3
51	DAB₃₈₉IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice. Immunopharmacology and Immunotoxicology, 2017, 39, 318-329.	1.1	2
52	Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. Journal of NeuroVirology, 2017, 23, 839-844.	1.0	17
53	Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Scientific Reports, 2017, 7, 14542.	1.6	93
54	The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0172415.	1.1	77

#	Article	IF	Citations
55	Intestinal Bacterial Antigens, Toxin-Induced Pathogenesis and Immune Cross-Reactivity in Neuromyelitis Optica and Multiple Sclerosis. , 2016, , 227-236.		3
56	Prognostic factors for long-term outcomes in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731666640.	0.5	11
57	Helicobacter pylori, Experimental Autoimmune Encephalomyelitis, and Multiple Sclerosis. , 2016, , 97-122.		2
58	A comparison of phase imaging and quantitative susceptibility mapping in the imaging of multiple sclerosis lesions at ultrahigh field. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 543-557.	1.1	38
59	The future of multiple sclerosis treatments. Expert Review of Neurotherapeutics, 2016, 16, 1341-1356.	1.4	7
60	Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices. Current Neurology and Neuroscience Reports, 2016, 16, 68.	2.0	15
61	Neurological Complications of Anti-TNF Treatments and Other Neurological Aspects of Inflammatory Bowel Disease. , 2016, , 211-225.		0
62	Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. JAMA Neurology, 2016, 73, 954.	4.5	17
63	Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis. Expert Review of Clinical Pharmacology, 2016, 9, 49-57.	1.3	7
64	Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 324-331.	0.9	95
65	Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research (discontinued), 2016, 8, 3448-59.	0.0	47
66	Cognitive Rehabilitation for Attention and Memory in people with Multiple Sclerosis: study protocol for a randomised controlled trial (CRAMMS). Trials, 2015, 16, 556.	0.7	13
67	MRIâ€Based Measurement of Brain Stem Crossâ€Sectional Area in Relapsingâ€Remitting Multiple Sclerosis. Journal of Neuroimaging, 2015, 25, 1002-1006.	1.0	7
68	Histogram analysis of quantitative T₁ and MT maps from ultrahigh field MRI in clinically isolated syndrome and relapsingâ€“remitting multiple sclerosis. NMR in Biomedicine, 2015, 28, 1374-1382.	1.6	8
69	TLR2 Stimulation Regulates the Balance between Regulatory T Cell and Th17 Function: A Novel Mechanism of Reduced Regulatory T Cell Function in Multiple Sclerosis. Journal of Immunology, 2015, 194, 5761-5774.	0.4	65
70	Development of a simple and sensitive HPLCâ€“UV method for the simultaneous determination of cannabidiol and Î”9-tetrahydrocannabinol in rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 2015, 114, 145-151.	1.4	56
71	Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study. BMJ Open, 2015, 5, e007806-e007806.	0.8	10
72	Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: A 7 Tesla MRI study. Journal of Magnetic Resonance Imaging, 2015, 41, 1065-1070.	1.9	37

#	Article	IF	Citations
73	Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e117.	3.1	86
74	Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFNÎ³/IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2015, 10, 457-467.	2.1	28
75	PEGylated IFNÎ²-1a in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy, 2015, 15, 1077-1084.	1.4	10
76	Helicobacter pylori infection reduces disease severity in an experimental model of multiple sclerosis. Frontiers in Microbiology, 2015, 6, 52.	1.5	54
77	What role does tobacco smoking play in multiple sclerosis disability and mortality? A review of the evidence. Neurodegenerative Disease Management, 2015, 5, 19-25.	1.2	14
78	Coordinate based meta-analysis does not show grey matter atrophy in narcolepsy. Neuroscience and Biobehavioral Reviews, 2015, 57, 297-298.	2.9	13
79	Effects of proâ€inflammatory cytokines on cannabinoid ‹scp›CB‹/scp›‹sub›1‹/sub› and ‹scp›CB‹/scp›‹sub›2‹/sub› receptors in immune cells. Acta Physiologica, 2015, 214, 63-74.	1.8	95
80	Functionally Relevant White Matter Degradation in Multiple Sclerosis: A Tract-based Spatial Meta-Analysis. Radiology, 2015, 275, 89-96.	3.6	39
81	Coordinate Based Meta-Analysis of Functional Neuroimaging Data Using Activation Likelihood Estimation; Full Width Half Max and Group Comparisons. PLoS ONE, 2014, 9, e106735.	1.1	20
82	Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 621-630.	1.5	13
83	Subjective discomfort in children receiving 3â€…T MRI and experienced adultsâ€™ perspective on childrenâ€™s tolerability of 7â€…T: a cross-sectional questionnaire survey. BMJ Open, 2014, 4, e006094.	0.8	28
84	Helminth Therapy for MS. Current Topics in Behavioral Neurosciences, 2014, 26, 195-220.	0.8	15
85	Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1091-1095.	0.9	41
86	DAB389IL-2 suppresses autoimmune inflammation in the CNS and inhibits T cell-mediated lysis of glial target cells. Experimental and Molecular Pathology, 2014, 96, 108-117.	0.9	3
87	Diagnosis and management of Neuro-BehÃ§etâ€™s disease: international consensus recommendations. Journal of Neurology, 2014, 261, 1662-1676.	1.8	236
88	Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nature Communications, 2014, 5, 5056.	5.8	137
89	The essential role of t cells in multiple sclerosis: A reappraisal. Biomedical Journal, 2014, 37, 34.	1.4	29
90	Diagnostic modalities in multiple sclerosis: Perspectives in children. Biomedical Journal, 2014, 37, 50.	1.4	11

#	Article	IF	Citations
91	Advances in the treatment of relapsing - Remitting multiple sclerosis. Biomedical Journal, 2014, 37, 41.	1.4	25
92	Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1219-1228.	1.5	9
93	The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease. Amino Acids, 2013, 45, 95-112.	1.2	13
94	Association of a deficit of arousal with fatigue in multiple sclerosis: Effect of modafinil. Neuropharmacology, 2013, 64, 380-388.	2.0	35
95	Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions ofC9ORF72. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 79-87.	0.9	57
96	Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome. Multiple Sclerosis Journal, 2013, 19, 896-903.	1.4	83
97	Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain, 2013, 136, 2298-2304.	3.7	127
98	Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment, 2013, 9, 539.	1.0	12
99	Coordinate Based Meta-Analysis of Functional Neuroimaging Data; False Discovery Control and Diagnostics. PLoS ONE, 2013, 8, e70143.	1.1	18
100	Association of Multiple sclerosis with Other Autoimmune Diseases. , 2013, , 341-356.		0
101	Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension. American Journal of Clinical and Experimental Immunology, 2013, 2, 234-44.	0.2	24
102	Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. Expert Opinion on Biological Therapy, 2012, 12, 1517-1531.	1.4	22
103	IL-12 inhibits glucocorticoid-induced T cell apoptosis by inducing GMEB1 and activating PI3K/Akt pathway. Immunobiology, 2012, 217, 118-123.	0.8	16
104	Fatigue in multiple sclerosis â€" A brief review. Journal of the Neurological Sciences, 2012, 323, 9-15.	0.3	183
105	Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2012, 12, 592-600.	2.0	19
106	Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjects. Multiple Sclerosis and Related Disorders, 2012, 1, 131-135.	0.9	4
107	Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2012, 7, 253-265.	2.1	27
108	Extra-Hippocampal Subcortical Limbic Involvement Predicts Episodic Recall Performance in Multiple Sclerosis. PLoS ONE, 2012, 7, e44942.	1.1	21

#	Article	IF	Citations
109	The Effects of Cannabinoids on Immune Cells, Responses and Diseases. , 2012, , 307-359.		0
110	A drug discovery case history of â€˜delta-9-tetrahydrocannabinol, cannabidiolâ€™. Expert Opinion on Drug Discovery, 2011, 6, 437-452.	2.5	6
111	Impact of exposure to interferon beta-1a on outcomes in patients with relapsingâ€“remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Therapeutic Advances in Neurological Disorders, 2011, 4, 3-14.	1.5	45
112	Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: No correlation with fatigue and sleepiness. Journal of the Neurological Sciences, 2011, 307, 127-131.	0.3	29
113	Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). British Journal of Pharmacology, 2011, 164, 1079-1106.	2.7	1,082
114	Central inflammation versus peripheral regulation in multiple sclerosis. Journal of Neurology, 2011, 258, 1518-1527.	1.8	25
115	Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders. Current Pharmaceutical Design, 2011, 17, 3191-3201.	0.9	4
116	Evaluation of an adjustment group forpeople with multiple sclerosis and lowmood: a randomized controlled trial. Multiple Sclerosis Journal, 2011, 17, 1250-1257.	1.4	62
117	TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function. Journal of Immunology, 2011, 187, 2278-2290.	0.4	152
118	Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurology, The, 2010, 9, 672-680.	4.9	70
119	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	0.6	86
120	Cytokines in Idiopathic Intracranial Hypertension CSF. Headache, 2010, 50, 323-325.	1.8	4
121	Are current diseaseâ€modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?. Journal of Neurochemistry, 2010, 115, 829-844.	2.1	51
122	Current and future disease-modifying therapies in multiple sclerosis. International Journal of Clinical Practice, 2010, 64, 637-650.	0.8	44
123	Multiple Sclerosis, Lymphoma and Nasopharyngeal Carcinoma: The Central Role of Epstein-Barr Virus?. European Neurology, 2010, 63, 29-35.	0.6	12
124	Autoimmune associations in multiple sclerosis. Nature Reviews Neurology, 2010, 6, 591-592.	4.9	17
125	Expression of Activity-Dependent Neuroprotective Protein in the Immune System: Possible Functions and Relevance to Multiple Sclerosis. NeuroImmunoModulation, 2010, 17, 120-125.	0.9	37
126	The Role of Osteopontin in Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS). Inflammation and Allergy: Drug Targets, 2010, 9, 249-256.	1.8	38

#	Article	IF	Citations
127	Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1349-1359.	1.4	159
128	Cannabinoids and experimental models of multiple sclerosis. Immunobiology, 2010, 215, 647-657.	0.8	33
129	Cannabinoids and the immune system: An overview. Immunobiology, 2010, 215, 588-597.	0.8	209
130	Interaction between cytokines, cannabinoids and the nervous system. Immunobiology, 2010, 215, 606-610.	0.8	59
131	Special Issue 8, 2010 introduction. Immunobiology, 2010, 215, 587.	0.8	2
132	Th17/Th1 phenotype in demyelinating disease. Cytokine, 2010, 50, 19-23.	1.4	51
133	Brain tractography using Q-ball imaging and graph theory: Improved connectivities through fibre crossings via a model-based approach. NeuroImage, 2010, 49, 2444-2456.	2.1	56
134	Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases. Inflammation and Allergy: Drug Targets, 2009, 8, 182-190.	1.8	43
135	Modulation of Regulatory T Cells in Health and Disease: Role of Toll-Like Receptors. Inflammation and Allergy: Drug Targets, 2009, 8, 124-129.	1.8	30
136	Hypothalamic involvement assessed by T1 relaxation time in patients with relapsingâ€”remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1442-1449.	1.4	35
137	Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain, 2009, 132, 239-249.	3.7	339
138	Glucocorticoids increase CD4⁺CD25^{high}cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2009, 119, 239-245.	1.0	87
139	Plasma endocannabinoid levels in multiple sclerosis. Journal of the Neurological Sciences, 2009, 287, 212-215.	0.3	94
140	Parasite immunomodulation in autoimmune disease: focus on multiple sclerosis. Expert Review of Clinical Immunology, 2009, 5, 487-489.	1.3	7
141	fMRI analysis of active, passive and electrically stimulated ankle dorsiflexion. NeuroImage, 2009, 44, 469-479.	2.1	106
142	Beta Interferon. , 2009, , 1-4.		0
143	A regularized twoâ€tensor model fit to low angular resolution diffusion images using basis directions. Journal of Magnetic Resonance Imaging, 2008, 28, 199-209.	1.9	31
144	Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurology, The, 2008, 7, 796-804.	4.9	438

#	Article	IF	Citations
145	Title is missing!. Journal of the Neurological Sciences, 2008, 271, 214-215.	0.3	0
146	Eye Movement Involvement in Parry-Romberg Syndrome: A Clinicopathologic Case Report. Strabismus, 2008, 16, 119-121.	0.4	9
147	Treatment of Neuromyelitis Optica With Rituximab. Archives of Neurology, 2008, 65, 1443.	4.9	445
148	Letter to the Editor: A case of dysphagia with clinically isolated syndrome. Multiple Sclerosis Journal, 2008, 14, 716-717.	1.4	0
149	Ehlersâ€"Danlos syndrome and multiple sclerosis: a possible association. Multiple Sclerosis Journal, 2008, 14, 567-570.	1.4	11
150	Increased Osteopontin Levels in the Cerebrospinal Fluid of Patients With Multiple Sclerosis. Archives of Neurology, 2008, 65, 633-5.	4.9	50
151	Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 437-441.	0.9	88
152	Validation of the Multiple Sclerosis International Quality of Life questionnaire. Multiple Sclerosis Journal, 2008, 14, 219-230.	1.4	159
153	Symptomatic Uveitis and Multiple Sclerosis. Neuro-Ophthalmology, 2008, 32, 49-54.	0.4	3
154	Stroop performance in multiple sclerosis: Information processing, selective attention, or executive functioning?. Journal of the International Neuropsychological Society, 2008, 14, 805-814.	1.2	61
155	Spotlight on teriflunomide. International MS Journal, 2008, 15, 62-8.	0.3	36
156	Multiple sclerosis findings in the spinal cord. Expert Review of Neurotherapeutics, 2007, 7, 1203-1211.	1.4	5
157	Reciprocal effects of IFN-Î² and IL-12 on STAT4 activation and cytokine induction in T cells. Journal of Leukocyte Biology, 2007, 81, 1562-1567.	1.5	7
158	Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochemical and Biophysical Research Communications, 2007, 364, 131-137.	1.0	119
159	A presenilin 1 mutation (Arg278Ser) associated with early onset Alzheimerâ€™s disease and spastic paraparesis. Journal of the Neurological Sciences, 2007, 260, 78-82.	0.3	12
160	Effect of DAB389IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. Journal of the Neurological Sciences, 2007, 263, 59-69.	0.3	19
161	Upper cervical spinal cord crossâ€sectional area in relapsing remitting multiple sclerosis: Application of a new technique for measuring crossâ€sectional area on magnetic resonance images. Journal of Magnetic Resonance Imaging, 2007, 26, 61-65.	1.9	37
162	Curcumin modulation of IFNâ€Î²2 and ILâ€12 signalling and cytokine induction in human T cells. Journal of Cellular and Molecular Medicine, 2007, 11, 1129-1137.	1.6	65

#	Article	IF	Citations
163	Atopic Optic Neuritis. Ocular Immunology and Inflammation, 2006, 14, 125-127.	1.0	10
164	SUNCT in Multiple Sclerosis. Cephalalgia, 2006, 26, 891-893.	1.8	17
165	Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus. Nature Genetics, 2006, 38, 1242-1244.	9.4	180
166	Deep gray matter and fatigue in MS. Journal of Neurology, 2006, 253, 896-902.	1.8	78
167	Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent. Journal of Leukocyte Biology, 2006, 80, 133-144.	1.5	27
168	Intrathecal gadolinium-enhanced magnetic resonance myelography in the detection of CSF leak. Neurology, 2006, 67, 1522-1522.	1.5	12
169	B Cells and Antibodies in Experimental Autoimmune Encephalomyelitis. , 2005, , 269-281.		1
170	The Neuron and Axon in Experimental Autoimmune Encephalomyelitis. , 2005, , 133-149.		0
171	Hormonal and Gender Influences on Experimental Autoimmune Encephalomyelitis. , 2005, , 547-560.		0
172	Cytokines in Experimental Autoimmune Encephalomyelitis. , 2005, , 283-311.		0
173	Spinal Cord Imaging in Multiple Sclerosis. Journal of Neuroimaging, 2005, 15, 94S-102S.	1.0	41
174	Astrocytes as antigen-presenting cells: expression of IL-12/IL-23. Journal of Neurochemistry, 2005, 95, 331-340.	2.1	119
175	Measurement of cervical spinal cord cross-sectional area by MRI using edge detection and partial volume correction. Journal of Magnetic Resonance Imaging, 2005, 21, 197-203.	1.9	58
176	A comparative audit of anticardiolipin antibodies in oligoclonal band negative and positive multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 378-380.	1.4	11
177	Adjuvants in EAE. , 2005, , 73-84.		2
178	Corpus callosum changes following shunting for hydrocephalus: case report and review of the literature. Clinical Neurology and Neurosurgery, 2005, 107, 351-354.	0.6	15
179	â€˜Importance samplingâ€™ in MS: Use of diffusion tensor tractography to quantify pathology related to specific impairment. Journal of the Neurological Sciences, 2005, 237, 13-19.	0.3	86
180	Environmental Influences in Experimental Autoimmune Encephalomyelitis. , 2005, , 523-546.		3

#	Article	IF	Citations
181	A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Multiple Sclerosis Journal, 2004, 10, 575-581.	1.4	182
182	Serum uric acid levels in optic neuritis. Multiple Sclerosis Journal, 2004, 10, 278-280.	1.4	35
183	Measurement of Spinal Cord Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2004, 14, 20S.	1.0	63
184	Measurement of Spinal Cord Atrophy in Multiple Sclerosis. , 2004, 14, 20-26.		46
185	Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis. Journal of Neurology, 2003, 250, 307-315.	1.8	54
186	Skeletal muscle myosin is the autoantigen for experimental autoimmune myositis. Experimental and Molecular Pathology, 2003, 74, 238-243.	0.9	15
187	The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurologica Scandinavica, 2003, 108, 401-406.	1.0	66
188	Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon Â-1a (Rebif) treatment trial. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1090-1094.	0.9	122
189	Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. American Journal of Ophthalmology, 2002, 134, 780-782.	1.7	26
190	Migraine and Raynaud Phenomenon: Possible Late Complications of Kawasaki Disease. Headache, 2002, 42, 227-229.	1.8	13
191	Modulation of Susceptibility and Resistance to an Autoimmune Model of Multiple Sclerosis in Prototypically Susceptible and Resistant Strains by Neutralization of Interleukin-12 and Interleukin-4, Respectively. Clinical Immunology, 2001, 98, 23-30.	1.4	44
192	INTERLEUKIN 15 STIMULATES PRODUCTION OF MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 BY HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS. Cytokine, 2001, 13, 244-247.	1.4	27
193	Cutting Edge: C3, a Key Component of Complement Activation, Is Not Required for the Development of Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis in Mice. Journal of Immunology, 2001, 166, 723-726.	0.4	82
194	Possible Role of Corticosteroids in Nervous System Plasticity: Improvement in Amblyopia After Optic Neuritis in the Fellow Eye Treated with Steroids. Neurorehabilitation and Neural Repair, 2001, 15, 223-227.	1.4	2
195	Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12. Journal of Neuroimmunology, 2000, 107, 1-7.	1.1	32
196	Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases. Multiple Sclerosis Journal, 2000, 6, 362-363.	1.4	6
197	Murine macrophages stimulated with central and peripheral nervous system myelin or purified myelin proteins release inflammatory products. Neuroscience Letters, 2000, 287, 171-174.	1.0	34
198	Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 378-381.	1.4	34

#	Article	IF	Citations
199	Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Current Eye Research, 2000, 20, 71-76.	0.7	19
200	Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 378-381.	1.4	1
201	Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Current Eye Research, 2000, 20, 71-6.	0.7	3
202	IL-12 reverses the suppressive effect of the CD40 ligand blockade on experimental autoimmune encephalomyelitis (EAE). Journal of the Neurological Sciences, 1999, 171, 60-64.	0.3	25
203	The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. European Journal of Immunology, 1998, 28, 2227-2233.	1.6	51
204	Absence of electromyographically detectable acute neuromuscular transmission defects after intramuscular interferon-Î³ administration. Journal of Neurology, 1998, 245, 333-334.	1.8	0
205	Pathogenesis of neuroimmunologic diseases. Immunologic Research, 1998, 17, 217-227.	1.3	43
206	Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunology Letters, 1998, 62, 25-31.	1.1	134
207	Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. Journal of Immunology, 1998, 161, 5097-104.	0.4	109
208	Serum Angiotensin-Converting Enzyme in Multiple Sclerosis. Archives of Neurology, 1997, 54, 1012-1015.	4.9	52
209	Tumor Necrosis Factor Î± and Lymphotoxin Î± Are Not Required for Induction of Acute Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 1997, 185, 2177-2182.	4.2	182
210	Luzindole, a Melatonin Receptor Antagonist, Suppresses Experimental Autoimmune Encephalomyelitis. Pathobiology, 1997, 65, 190-194.	1.9	53
211	Lymphocyte-specific inducible expression of potassium channel beta subunits. Journal of Neuroimmunology, 1997, 77, 8-16.	1.1	17
212	Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline. Journal of the Neurological Sciences, 1996, 143, 14-18.	0.3	18
213	Astrocytes and Microglia Produce Interleukin-12 p40. Annals of the New York Academy of Sciences, 1996, 795, 328-333.	1.8	47
214	Clinical and subclinical neurological involvement in children of conjugal multiple sclerosis patients. Multiple Sclerosis Journal, 1995, 1, 170-172.	1.4	4
215	Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: A rationale for light therapy in multiple sclerosis. Medical Hypotheses, 1995, 45, 455-458.	0.8	25
216	A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. Journal of the Neurological Sciences, 1995, 130, 178-182.	0.3	28

#	Article	IF	Citations
217	Effects of the Angiotensin Converting Enzyme Inhibitor Captopril on Experimental Autoimmune Encephalomyelitis. Immunopharmacology and Immunotoxicology, 1995, 17, 471-491.	1.1	59
218	Urinary Free Kappa Light Chain Levels in Chronic Progressive Multiple Sclerosis. Pathobiology, 1994, 62, 29-33.	1.9	11
219	Olfactory disturbances as the initial or most prominent symptom of multiple sclerosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1011-1012.	0.9	34
220	Intracolonic Vancomycin for Pseudomembranous Colitis. New England Journal of Medicine, 1993, 329, 583-583.	13.9	72